Fortress Biotech旗下子公司Cyprium Therapeutics宣布,已成功完成一张罕见儿科疾病优先审评券的出售交易,成交金额达2.05亿美元。此次交易标志着公司在资产优化战略方面取得重要进展,为后续研发管线注入强劲资金支持。
Fortress Biotech旗下子公司Cyprium Therapeutics宣布,已成功完成一张罕见儿科疾病优先审评券的出售交易,成交金额达2.05亿美元。此次交易标志着公司在资产优化战略方面取得重要进展,为后续研发管线注入强劲资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.